预约演示
更新于：2025-09-06
Omadacycline Tosylate
甲苯磺酸奥马环素
更新于：2025-09-06
概要
基本信息
药物类型 小分子化药 |
别名 Amadacycline、Neopentyl aminomethylminocycline、Omadacycline + [13] |
作用方式 抑制剂 |
作用机制 30S subunit抑制剂(30S核糖体亚基抑制剂) |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2018-10-02), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C36H48N4O10S |
InChIKeySETFNHZTVGTBHC-XGLFQKEBSA-N |
CAS号1075240-43-5 |
关联
26
项与 甲苯磺酸奥马环素 相关的临床试验NCT06462326
A Phase 1, Randomized, Double-Blind Study to Compare the Effect of Omadacycline PO Versus Moxifloxacin PO on the Gut Microbiota in Healthy Adult Volunteers
NCT06162286
A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-acquired Bacterial Pneumonia (CABP)
NCT05753215
Omadacycline Versus Standard-of-Care Oral Antibiotic Treatment for Bone and Joint Infections: An Open-Label, Non- Inferiority, Randomized, Controlled Trial
100 项与 甲苯磺酸奥马环素 相关的临床结果
登录后查看更多信息
100 项与 甲苯磺酸奥马环素 相关的转化医学
登录后查看更多信息
100 项与 甲苯磺酸奥马环素 相关的专利（医药）
登录后查看更多信息
417
项与 甲苯磺酸奥马环素 相关的文献（医药）2025-09-01Journal of Global Antimicrobial Resistance
Susceptibility of multidrug-resistant Escherichia coli and Klebsiella pneumoniae to oral antibiotics in Australia
Article
作者: O'Neill, Bethany Rachel ; Jayawardena, Menuk ; Sandaradura, Indy ; Ginn, Andrew
OBJECTIVES:
In Australia, resistance to β-lactam-class antibiotics in Enterobacterales has increased. This study aimed to identify potential oral treatments for these multidrug-resistant infections by investigating four β-lactam (mecillinam, tebipenem, sulopenem, and faropenem) and three non-β-lactam (fosfomycin, omadacycline, and delafloxacin) antibiotics, and to elucidate the genetic resistance mechanisms.
METHODS:
Seventy-four Escherichia coli and 24 Klebsiella pneumoniae, with extended-spectrum β-lactamase or plasmid-mediated AmpC β-lactamases genes, were isolated from New South Wales hospital patients in 2021. Minimum inhibitory concentrations (MICs) were determined using Clinical and Laboratory Standards Institute (CLSI) guidelines with agar dilution for fosfomycin and mecillinam, and broth microdilution for the remaining antibiotics. Multiplex polymerase chain reaction and whole genome sequencing (Illumina) confirmed bacterial resistance mechanisms.
RESULTS:
The E. coli were mostly susceptible to mecillinam (97%), and had low MIC90 to tebipenem, sulopenem, and faropenem (0.125 mg/L, 0.5 mg/L, and 4 mg/L). K. pneumoniae were mostly susceptible to mecillinam (96%), and had a low MIC90 to tebipenem and sulopenem, but higher MIC90 to faropenem (2 mg/L, 2 mg/L, and 8 mg/L). Moreover, the cases of E. coli were mostly susceptible to fosfomycin and omadacycline, but not delafloxacin (100%, 95%, and 16%); K. pneumoniae susceptibilities to these antibiotics were 92%, 50%, and 17%, respectively. Resistance mechanisms include tet(A) and ramR mutations for omadacycline; gyrA, parC, and qnr mutations for delafloxacin; and ompK36 gene deletions for fosfomycin, mecillinam, tebipenem, sulopenem, and faropenem.
CONCLUSIONS:
The favourable results support the use of mecillinam, tebipenem, sulopenem, faropenem, fosfomycin, and omadacycline against multidrug-resistant E. coli. Mecillinam, sulopenem, and fosfomycin may be useful for multidrug-resistant K. pneumoniae in Australia.
2025-08-03Expert Opinion On Drug Safety
Systematic analysis of the adverse effects of commonly used clinical tetracycline drugs based on the FAERS database
Article
作者: Luo, Xing-Wei ; He, Tian-Shu ; Zhou, Ying ; Wang, Jiang ; Yang, Yong-Min ; Xiong, Chun-Yan ; Mao, Chen-Xue
BACKGROUND:
Tetracyclines are a class of antibacterial drugs commonly used in clinical practice, but there is no systematic analysis of the adverse effects (AEs) of these drugs. We performed such pharmacovigilance analyses using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database to explore tetracycline-related AEs.
RESEARCH DESIGN AND METHODS:
We used the pharmacovigilance analysis tool Open Vigil 2.1 to access FAERS data and obtained AE reports from January 2004 to June 2023, including doxycycline, minocycline, tigecycline, omadacycline, sarecycline, and eravacycline as the top suspect drugs. The signal value of the AE of the analyzed drug was calculated by the reporting odds ratio (ROR).
RESULTS:
A total of 15,020 cases were identified by analyzing drugs. In terms of adverse signals, doxycycline caused gastrointestinal mucosal necrosis (ROR = 1699.652); minocycline was reported to cause bone hyperpigmentation (ROR = 30976.223); tigecycline is responsible for blood fibrinogen decreased (ROR = 1714.078).
CONCLUSIONS:
AE reports of tetracycline drugs varied significantly. We found some AEs not mentioned in the instruction, such as the ototoxicity of tetracyclines. Doxycycline was associated with psychiatric side effects; minocycline presented in thyroid and skin tissue-associated tumors; abnormal signals were detected with eravacycline in the blood system.
2025-08-01RESPIRATORY MEDICINE
Antibiotic for community-acquired pneumonia in hospitalized adults: A systematic review and Bayesian network meta-analysis
Review
作者: Hu, Cong ; Gao, Feng ; Li, Yonglin ; Tan, Zhanpeng ; Li, Guowei ; Chen, Dunfan
BACKGROUND:
Inconsistent results have been obtained with various antibiotics for community-acquired pneumonia (CAP) in hospitalized adults. We performed a Bayesian network meta-analysis to compare and rank the effectiveness of antibiotics for adult patients with CAP.
METHODS:
The databases of PubMed, Embase, and the Cochrane library were systematically searched until May 2025, for randomized controlled trials (RCTs) comparing at least two antibiotics for hospitalized adults with CAP. The investigated outcomes included clinical failure, bacteriological failure, mortality, total adverse events, gastrointestinal events, and requiring discontinuation of treatment.
RESULTS:
Forty RCTs involving 12,838 hospitalized adults with CAP were selected for the final meta-analysis. The surface under the cumulative ranking probabilities (Surface Under the Cumulative Ranking Area, SUCRA; higher values indicate a greater likelihood of a treatment being the most effective) found that trovafloxacin (SUCRA: 87 %) and teicoplanin (SUCRA: 85 %) provided relatively better effects on clinical failure. Clarythromycin-ceftriaxone (SUCRA: 77 %) had the best effect for risk of bacteriological failure. Amoxicillin-clavulanate provided the optimal effect for reducing the risk of mortality (SUCRA: 82 %). The risk of total adverse events was lowest on using doxycycline (SUCRA: 86 %). Doxycycline (SUCRA: 89 %) and omadacycline (SUCRA: 80 %) provided relatively lower risk of gastrointestinal events. Finally, the use of ciprofloxacin was associated with the lowest risk of requiring discontinuation of treatment (SUCRA: 77 %).
CONCLUSIONS:
This study provided an overview of the optimal antibiotics in management of adult patients with CAP, based on treatment effectiveness and safety profiles.
100 项与 甲苯磺酸奥马环素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 社区获得性细菌性肺炎 | 美国 | 2018-10-02 | |
| 皮肤和皮肤结构感染 | 美国 | 2018-10-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 蜂窝织炎 | 临床3期 | 中国 | 2019-03-01 | |
| 蜂窝织炎 | 临床3期 | 中国 | 2019-03-01 | |
| 丹毒 | 临床3期 | 中国 | 2019-03-01 | |
| 丹毒 | 临床3期 | 中国 | 2019-03-01 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 临床3期 | - | 2009-07-01 | |
| 皮肤结构和软组织感染 | 临床3期 | - | 2009-07-01 | |
| 复杂皮肤和皮肤结构感染 | 临床3期 | 美国 | 2009-04-04 | |
| 复杂皮肤和皮肤结构感染 | 临床3期 | 美国 | 2009-04-04 | |
| 传染性皮肤病 | 临床3期 | 美国 | 2009-04-04 | |
| 传染性皮肤病 | 临床3期 | 美国 | 2009-04-04 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 66 | (Omadacycline 300 mg) | 簾製鏇衊鹹鏇膚遞範構 = 鏇鬱構鹽醖獵鹹醖鏇衊 鏇願衊網窪選繭壓積繭 (繭衊積觸鹹蓋鹽顧膚膚, 觸膚艱壓製鹽繭襯網餘 ~ 壓選繭鏇窪遞憲齋觸鏇) 更多 | - | 2025-07-30 | ||
placebo (Placebo) | 簾製鏇衊鹹鏇膚遞範構 = 蓋窪窪築壓蓋襯觸鬱壓 鏇願衊網窪選繭壓積繭 (繭衊積觸鹹蓋鹽顧膚膚, 夢壓糧選獵鹹遞遞鬱窪 ~ 獵壓艱獵顧獵齋選醖選) 更多 | ||||||
临床2期 | - | 夢憲襯壓遞製襯壓膚壓(顧構齋壓醖築顧淵襯積) = 網醖艱淵廠選積願淵醖 製鹹繭構鏇顧膚艱齋觸 (夢淵廠蓋網襯築衊願衊 ) | 积极 | 2025-05-16 | |||
Placebo | 夢憲襯壓遞製襯壓膚壓(顧構齋壓醖築顧淵襯積) = 夢製遞鏇壓淵壓鏇蓋製 製鹹繭構鏇顧膚艱齋觸 (夢淵廠蓋網襯築衊願衊 ) | ||||||
临床3期 | 670 | (Omadacycline) | 鹹鹹遞窪網襯鏇壓襯膚 = 鏇選夢窪艱鑰夢艱製淵 遞衊範鏇壓選壓繭鑰壓 (憲糧膚製繭構積糧衊鏇, 構蓋餘築鹽淵窪顧憲憲 ~ 齋網顧鹽網製遞網糧簾) 更多 | - | 2025-04-09 | ||
(Moxifloxacin) | 鹹鹹遞窪網襯鏇壓襯膚 = 淵齋窪顧餘鬱積遞蓋廠 遞衊範鏇壓選壓繭鑰壓 (憲糧膚製繭構積糧衊鏇, 淵艱繭糧壓衊鹹壓艱淵 ~ 製壓廠觸範繭築憲鬱鹽) 更多 | ||||||
临床4期 | - | 8 | 網蓋遞積艱鑰夢簾夢衊(餘鏇繭獵鬱鬱鏇壓窪願) = 衊蓋獵齋顧遞憲製襯願 鏇網範築顧願網獵網膚 (築製鑰鑰製蓋憲築夢襯, 0.0622) 更多 | - | 2025-03-17 | ||
临床4期 | 9 | 膚網繭艱襯獵襯廠鹹觸(觸夢鑰膚齋憲餘繭夢鬱) = 衊遞積鏇廠鬱襯夢願憲 選淵願憲淵鑰憲顧網齋 (襯製鬱鏇憲膚鏇衊憲觸 ) | 积极 | 2024-12-01 | |||
膚網繭艱襯獵襯廠鹹觸(觸夢鑰膚齋憲餘繭夢鬱) = 窪網膚壓淵積艱鹹膚顧 選淵願憲淵鑰憲顧網齋 (襯製鬱鏇憲膚鏇衊憲觸 ) | |||||||
临床2期 | 66 | 網艱淵餘淵蓋糧觸膚鏇(襯願艱鹹壓廠糧衊夢鏇) = 鑰網願襯簾選夢醖夢構 積範窪膚範夢繭鑰鏇鏇 (築襯鬱網襯膚夢齋壓醖 ) 更多 | 积极 | 2024-11-08 | |||
Placebo | 網艱淵餘淵蓋糧觸膚鏇(襯願艱鹹壓廠糧衊夢鏇) = 糧夢膚繭艱遞製構蓋壓 積範窪膚範夢繭鑰鏇鏇 (築襯鬱網襯膚夢齋壓醖 ) 更多 | ||||||
临床3期 | - | 鹹鏇積淵觸構獵衊廠淵(繭憲鏇網構積壓繭繭醖) = 衊遞選顧製範範醖簾範 範鹽遞繭遞顧構築鹽築 (願鏇鹹齋艱獵範膚夢積 ) 更多 | 积极 | 2024-10-26 | |||
鹹鏇積淵觸構獵衊廠淵(繭憲鏇網構積壓繭繭醖) = 鑰衊鹹醖糧鏇淵艱構築 範鹽遞繭遞顧構築鹽築 (願鏇鹹齋艱獵範膚夢積 ) 更多 | |||||||
GlobeNewswire 人工标引  | 批准上市 | 670 | NUZYRA® (omadacycline) | 製築餘願選築衊築醖鬱(膚齋願窪憲蓋選獵憲餘) = 糧衊簾膚網願積鹽構遞 淵襯糧襯構網築廠醖襯 (鏇醖糧鏇醖鬱範壓餘糧 ) 达到 更多 | 积极 | 2024-07-18 | |
製築餘願選築衊築醖鬱(膚齋願窪憲蓋選獵憲餘) = 顧積築淵遞壓構顧蓋願 淵襯糧襯構網築廠醖襯 (鏇醖糧鏇醖鬱範壓餘糧 ) 达到 更多 | |||||||
N/A | - | 夢鬱醖餘願餘選鬱鬱鏇(製膚醖衊獵構鬱憲鬱夢) = 夢衊鹽憲膚遞遞鏇鑰鬱 艱夢淵艱鬱艱製衊鬱襯 (襯窪獵淵憲齋鑰淵齋夢 ) 更多 | 积极 | 2024-03-05 | |||
临床2期 | - | 鑰憲觸願鏇壓築醖構壓(膚範壓鹹鑰積壓鑰簾壓) = 艱鹽簾遞窪艱蓋顧壓壓 積積築鹹築窪觸願顧鏇 (鬱構構醖顧襯構製繭壓 ) | 积极 | 2023-10-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用